Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Apremilast in Moderate Plaque Psoriasis
NCT04908475Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 4 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Jun 2021; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04908475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908475.